Reviews/Rheumatoid Arthritis Targeted Therapy/Treat-to-target strategy improves outcomes versus routine care in rheumatoid arthritis
T2T Strategy · RA-T2T-01 · v2
The claim says that steering rheumatoid arthritis treatment toward a set target beats ordinary care on both joint-damage (radiographic) and physical-function outcomes. In this corpus only two papers actually compare target-driven care against ordinary care: one real-world comparison [6] found more patients reaching remission and slightly better quality of life under the targeted approach, and one randomised trial [9] where the targeted approach did not beat ordinary care on its main goal and showed only a non-significant hint of a function benefit. Many other papers [5][7][8][12] follow only target-driven patients and show they can reach good joint and function outcomes, but with no comparison group they cannot show the strategy is better than ordinary care. Crucially, none of the head-to-head papers measured joint damage on X-ray, and one paper [4] found that sticking to the target was not linked to less joint damage. So the evidence points in a generally favourable direction for function and remission but leaves the joint-damage half of the claim untested against ordinary care.
Only two included papers set target-driven care against routine care. In [6], a real-world comparison, 46% reached SDAI remission under treat-to-target versus 31% under routine care, with a significant EQ-5D difference at two years. In the cluster-randomised trial [9], the primary sustained-CDAI-low-disease-activity endpoint was reached by 36.9% (T2T) versus 40.3% (routine care), with only a trend toward faster HAQ-DI improvement. Single-arm cohorts show target-driven care attains good structural and functional outcomes — [5] reports structural remission in 49.7% and functional remission in 63.4%, and [7], [8] and [12] report sustained functional and quality-of-life gains — but without a comparator they cannot establish superiority. Paper [4] found target adherence associated with remission and physical functioning but not with radiographic progression. The contested point: The evidence divides on whether reaching a target beats routine care rather than merely achieving good outcomes: the one observational comparison [6] favours treat-to-target while the one randomised comparison [9] missed its primary endpoint and left the functional advantage as a non-significant trend. The radiographic-versus-routine-care half of the claim is the sharpest fault line, being untested here and, for adherence, actively unsupported in [4].
All 13 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Rheumatoid Arthritis Targeted Therapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The routine-care comparator is present in only two included papers; [6] is an observational historical-control design confounded by secular treatment improvement, and [9] is an RCT that MISSED its primary endpoint (36.9% vs 40.3%). The direct comparative base for 'versus routine care' is thin and partly null.
The radiographic limb of the claim is unsupported: no included T2T-vs-routine-care paper measured radiographic progression, and [4] found T2T adherence was NOT associated with radiographic progression, contradicting half the claim.
Where it remains uncertain. The only randomised comparison versus routine care [9] missed its primary endpoint (36.9% vs 40.3%) with just a functional trend, and no head-to-head paper measured radiographic progression while [4] found target adherence unrelated to it.
Aleatory
The randomised comparison [9] enrolled only 284 patients (130 T2T vs 154 routine care), so chance variation around endpoints reaching 36.9% vs 40.3% is wide.
Epistemic
No included head-to-head paper ([6],[9]) measured radiographic progression, leaving the joint-damage half of the claim without comparative data.
The load-bearing papers from a corpus of 13, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Directly undercuts the radiographic limb: T2T implementation was not associated with radiographic progression.
“No such association was found for radiographic progression.”
Panel auditInternal validity: medium · scope of inference: Early RA patients in a T2T trial, effect of patient-physician discordance on T2T adherence and outcomes.Key limitations: no routine-care comparator · secondary analysis · T2T applied on only ~50% of visits
T2T attains structural and functional remission, but single-arm with no routine-care comparator.
“At week 52, structural remission (ΔmTSS/yr ≤0.5) was achieved in 49.7% of the patients, functional remission (HAQ-DI ≤0.5) in 63.4% and LDA in 51.0%.”
Panel auditInternal validity: low · scope of inference: MTX-naive elderly-onset RA patients treated to a low-disease-activity target in one centre.Key limitations: no comparator · single centre · elderly-onset subgroup only · 52-week horizon
Only direct T2T-vs-routine-care comparison showing benefit (remission and HRQoL), but observational historical-control design and no radiographic outcome.
“At 2years, the proportion of patients achieving SDAI remission was 46% in the T2T cohort compared to 31% in the routine care cohort.”
Panel auditInternal validity: medium · scope of inference: Early, DMARD-naive RA patients in Norwegian clinical practice, T2T versus a historical routine-care cohort.Key limitations: non-randomised historical control · no radiographic outcome reported · functional signal is HRQoL not HAQ
Improvements are within-cohort over time with no routine-care comparison, so the claim's contrast is not tested.
Panel auditInternal validity: low · scope of inference: Established RA patients in daily practice managed by a T2T strategy from 2005 to 2014.Key limitations: no comparator · single-arm · concurrent new therapies confound trend
4 of 13 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The functional-versus-routine-care limb has modest and partly null support while the radiographic-versus-routine-care limb is untested in this corpus, so the conjunctive claim is only partially carried.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No radiographic comparison versus routine care. The claim asserts a radiographic benefit versus routine care, but no included head-to-head paper measured radiographic progression and [4] found no association with target adherence. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised trial of treat-to-target versus routine care with radiographic progression (e.g. van der Heijde-modified Sharp score) as a pre-specified primary endpoint.
Open question: Does a treat-to-target strategy reduce radiographic progression compared with routine care? Why it is still open: No head-to-head paper in the corpus ([6],[9]) measured radiographic outcomes, and [4] found target adherence was not associated with radiographic progression.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19